Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...

Notable LLMs include GPT-4o by Open AI, Claude 3.5 Sonnet by Anthropic, and Gemini by Google. This scoping review aims to synthesize the current applications and potential uses of LLMs in patient ...

An artificial intelligence (AI) tool to help doctors identify high-risk heart patients will soon be rolled out on a trial basis in England after a study found it can accurately predict the risk ...

leading to heart failure in many patients—50% of whom do not survive beyond five years. The need for innovative therapies is urgent. The new therapeutic approach aims to improve heart function ...

Additionally, patients with heart diseases other than CHD, HF, and AF were excluded due to small sample sizes, which would not allow for robust estimations. Baseline patient characteristics were ...

A professor in ETSU’s Quillen College of Medicine was recently awarded a significant grant to research a potential treatment for heart failure.

The findings point to the possibility of developing such immunotherapies for heart failure in patients who have experienced a heart attack or other injury. A new study from Washington University ...

We are hopeful our study will lead to clinical trials investigating this immunotherapy strategy in heart failure patients." Fibroblasts have many roles in the heart, and parsing out the ...

Oral semaglutide, sold as Rybelsus, reduced the risk of a group of cardiovascular events by 14% compared with placebo in certain patients with ... to add reducing heart failure and related ...